BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/380/0.1/21.06.24 | Delayed Deutsche Boerse AG 18:52:34 19/06/2024 BST | ||
| 8.15 EUR | -4.00% |
|
| Current month | +26.72% | ||
| 1 month | +38.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 8.15 | -4.00% |
| 18/06/24 | 8.49 | -6.70% |
| 17/06/24 | 9.1 | -5.99% |
| 14/06/24 | 9.68 | +3.31% |
| 13/06/24 | 9.37 | +2.40% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 06:52 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM3RMW |
| ISIN | DE000VM3RMW5 |
| Date issued | 09/10/2023 |
| Strike | 380 $ |
| Maturity | 21/06/2024 (2 Days) |
| Parity | 10 : 1 |
| Emission price | 2.89 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.94 € |
|---|---|
| Lowest since issue | 1.84 € |
| Spread | 0.22 € |
| Spread % | 2.63% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Warrants
- Warrant